Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort

Blood blood.2024025834.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2787.

https://doi.org/10.1182/blood-2023-186947

Published: 2023

Journal Articles

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High Rates of MRD-Negative Remission in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Irrespective of Age

Ioannis Mantzaris, Mendel Goldfinger, Nishi Shah, Annemarie Munoz, Aradhika Dhawan, Nicole Chambers, Karen Fehn, Joel Victor, Aditi Shastri, Kira Gritsman, Noah Kornblum, Alejandro Sica, Dennis L Cooper, Amit Verma, Mimi Kim, Ulrich Steidl, Eric J Feldman, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4257.

https://doi.org/10.1182/blood-2023-188176

Published: 2023

Journal Articles

Comparison of the Prognostic Performance of European Leukemianet 2017 and 2022 Classifications in a Minority-Rich Population of Adult Patients with Acute Myeloid Leukemia

Kateryna Fedorov, Alexander Sisto, Josette Kamel, Mark Forsberg, Kith Pradhan, Nishi Shah, Aditi Shastri, Mendel Goldfinger, Noah Kornblum, Alejandro Sica, Dennis L Cooper, Kira Gritsman, Amit K. Verma, Eric J Feldman, Marina Y. Konopleva, Ioannis Mantzaris

Blood (2023) 142 (Supplement 1): 2968.

https://doi.org/10.1182/blood-2023-180856

Published: 2023

Journal Articles

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

Blood (2023) 142 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2023-185379

Published: 2023

Journal Articles

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Blood (2023) 142 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2023-181130

Published: 2023

Journal Articles

High PD-L1 Expression May be Associated with Worse Overall Prognosis in Acute Myeloid Leukemia

Josette M Kamel, Mendel Goldfinger, Jiani Chai, Jui Choudhuri, Marina Y. Konopleva, Eric J Feldman, Ioannis Mantzaris, Dennis L Cooper, Aditi Shastri, Nishi Shah, Noah Kornblum, Kira Gritsman, Alejandro Sica, Yanhua Wang, Xuejun Tian, Amit Verma, Swati Goel

Blood (2023) 142 (Supplement 1): 6050.

https://doi.org/10.1182/blood-2023-188243

Published: 2023

Journal Articles

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS: Assessment of Leukemia Stem Cell Eradication By High-Resolution MRD Assay

Blood (2022) 140 (Supplement 1): 3360–3361.

https://doi.org/10.1182/blood-2022-167849

Published: 2022

Journal Articles

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma

Hanlon Sia, Peter T. Tan, Joshua Richter, Phoebe Joy Ho, Tara Cochrane, Hang Quach, Binod Dhakal, Igor Proscurshim, Tony Jiang, Emaryn Mancino, Yacine Salhi, Sammicheli Stefano, Girish Gudi, Andrew Garton, Eric J. Feldman, Andrew Spencer

Blood (2022) 140 (Supplement 1): 10182–10184.

https://doi.org/10.1182/blood-2022-157585

Published: 2022

Journal Articles

Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL

Sammicheli Stefano, Camille Grandclement, Valentina Labanca, Stefania De Angelis, Carole Estoppey, Myriam Chimen, Blandine Pouleau, Perrine Suere, Emilie Nallet, Ankita Srivastava, Eric J. Feldman, Igor Proscurshim, Cyril Konto, Eugene Zhukovsky, Mario Perro

Blood (2022) 140 (Supplement 1): 6237–6238.

https://doi.org/10.1182/blood-2022-162201

Published: 2022

Journal Articles

A Non-Cytotoxic Regimen Using a Weekly Low Dose Decitabine and Venetoclax for MDS and AML in a Real World Cohort

David Levitz, Kateryna Fedorov, Kith Pradhan, Lauren C Shapiro, Aditi Shastri, Kira Gritsman, Nishi Shah, Noah Kornblum, R. Alejandro Sica, Ira Braunschweig, Marina Konopleva, Eric J. Feldman, Amit Verma, Ioannis Mantzaris, Yogenthiran Saunthararajah, Mendel Goldfinger

Blood (2022) 140 (Supplement 1): 6218–6219.

https://doi.org/10.1182/blood-2022-170059

Published: 2022

Journal Articles

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2022) 140 (Supplement 1): 7264–7266.

https://doi.org/10.1182/blood-2022-157525

Published: 2022

Journal Articles

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia

Daniel J. DeAngelo, Brian A. Jonas, Jane L. Liesveld, Dale L. Bixby, Anjali S. Advani, Paula Marlton, John L. Magnani, Helen M. Thackray, Eric J. Feldman, Michael E. O’Dwyer, Pamela S. Becker

Blood (2022) 139 (8): 1135–1146.

https://doi.org/10.1182/blood.2021010721

Published: 2022

Includes: Supplemental data

Journal Articles

Low-Dose Weekly Decitabine and Venetoclax in TP53-Mutated Myeloid Malignancies

Lauren C Shapiro, Ioannis Mantzaris, Aditi Shastri, R. Alejandro Sica, Lizamarie Bachier-Rodriguez, Noah Kornblum, Kira Gritsman, Eric J. Feldman, Amit Verma, Ira Braunschweig, Yogenthiran Saunthararajah, Mendel Goldfinger

Blood (2021) 138 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2021-145960

Published: 2021

Journal Articles

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Daniel J. DeAngelo, MD PhD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD, Anjali S. Advani, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Michael E O'Dwyer, MD, William E. Fogler, PhD, John L. Magnani, PhD, Mary M Chen, MD PhD, Eric J. Feldman, MD, Helen M Thackray, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2690.

https://doi.org/10.1182/blood-2019-123744

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MDPhD, Gail J. Roboz, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Sangmin Lee, MD, Michael P. Rettig, PhD, Tae H. Han, PhD, Jeanmarie Guenot, PhD, Eric J. Feldman, MD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 1455.

https://doi.org/10.1182/blood-2018-99-111529

Published: 2018

Journal Articles

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Harry P. Erba, MD PhD, Moshe Y Levy, MD, Sumithira Vasu, MBBS, Anthony S. Stein, MD, Amir T. Fathi, MD, Michael B. Maris, MD, Anjali Advani, MD, Stefan Faderl, MD, Scott E. Smith, MD PhD, Brent L. Wood, MD PhD, Roland B. Walter, MD PhD, Jay Yang, MD, William B. Donnellan, MD, Eric J. Feldman, MD, Jenna L Voellinger, PhD, Farhad Ravandi, MD

Blood (2016) 128 (22): 211.

https://doi.org/10.1182/blood.V128.22.211.211

Published: 2016

Journal Articles

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

Jay Yang, MD, Farhad Ravandi, MD, Anjali Advani, MD, Sumithira Vasu, MBBS, Roland B. Walter, MD PhD, Stefan Faderl, MD, Anthony S. Stein, MD, Harry P. Erba, MD PhD, Amir T. Fathi, MD, William B. Donnellan, MD, Moshe Y Levy, MD, Scott E. Smith, MD PhD, Brent L. Wood, MD PhD, Eric J. Feldman, MD, Jenna L Voellinger, PhD, Michael B. Maris, MD

Blood (2016) 128 (22): 340.

https://doi.org/10.1182/blood.V128.22.340.340

Published: 2016

Journal Articles

SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML

May S.K. Sutherland, PhD, Changpu Yu, Christine O'Day, PhD, Steve Alley, PhD, Martha Anderson, Kim Emmerton, Weipeng Zeng, Megan M. O'Meara, MD, Eric J. Feldman, MD, Dana A. Kennedy, Maureen C. Ryan, PhD, Dennis Benjamin, PhD

Blood (2015) 126 (23): 3785.

https://doi.org/10.1182/blood.V126.23.3785.3785

Published: 2015

NARROW

A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort

A STAT3 Degrader Demonstrates Pre-Clinical Efficacy in Venetoclax Resistant Acute Myeloid Leukemia

Venetoclax Combined with “7+3” Induction Chemotherapy Induces High Rates of MRD-Negative Remission in Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Irrespective of Age

Comparison of the Prognostic Performance of European Leukemianet 2017 and 2022 Classifications in a Minority-Rich Population of Adult Patients with Acute Myeloid Leukemia

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

High PD-L1 Expression May be Associated with Worse Overall Prognosis in Acute Myeloid Leukemia

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS: Assessment of Leukemia Stem Cell Eradication By High-Resolution MRD Assay

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma

Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL

A Non-Cytotoxic Regimen Using a Weekly Low Dose Decitabine and Venetoclax for MDS and AML in a Real World Cohort

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia

Low-Dose Weekly Decitabine and Venetoclax in TP53-Mutated Myeloid Malignancies

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

SGN-CD33A in Combination with Hypomethylating Agents Is Highly Efficacious in Preclinical Models of AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only